Herpes simplex virus type 1 (HSV-1) glycoprotein C (gC-1) elicits a largely serotype-specific immune response directed against previously described determinants designated antigenic sites I and II. To more precisely define these two immunodominant antigenic regions of gC-1 and to determine whether the homologous HSV-2 glycoprotein (gC-2) has similarly situated antigenic determinants, viral recombinants containing gC chimeric genes which join site I and site II of the two serotypes were constructed. The antigenic structure of the hybrid proteins encoded by these chimeric genes was studied by using gC-1-and gC-2-specific monoclonal antibodies (MAbs) in radioimmunoprecipitation, neutralization, and flow cytometry assays. The results of these analyses showed that the reactivity patterns of the MAbs were consistent among the three assays, and on this basis, they could be categorized as recognizing type-specific epitopes within the C-terminal or N-terminal half of gC-1 or gC-2. All MAbs were able to bind to only one or the other of the two hybrid proteins, demonstrating that gC-2, like gC-1, contains at least two antigenic sites located in the two halves of the molecule and that the structures of the antigenic sites in both molecules are independent and rely on limited type-specific regions of the molecule to maintain epitope structure. To fine map amino acid residues which are recognized by site I type-specific MAbs, point mutations were introduced into site I of the gC-1 or gC-2 gene, which resulted in recombinant mutant glycoproteins containing one or several residues from the heterotypic serotype in an otherwise homotypic site I background. The recognition patterns of the MAbs for these mutant molecules demonstrated that (i) single amino acids are responsible for the type-specific nature of individual epitopes and (ii) epitopes are localized to regions of the molecule which contain both shared and unshared amino acids. Taken together, the data described herein established the existence of at least two distinct and structurally independent antigenic sites in gC-1 and gC-2 and identified subtle amino acid sequence differences which contribute to type specificity in antigenic site I of gC.
containing gC chimeric genes which join site I and site II of the two serotypes were constructed. The antigenic structure of the hybrid proteins encoded by these chimeric genes was studied by using gC-1-and gC-2-specific monoclonal antibodies (MAbs) in radioimmunoprecipitation, neutralization, and flow cytometry assays. The results of these analyses showed that the reactivity patterns of the MAbs were consistent among the three assays, and on this basis, they could be categorized as recognizing type-specific epitopes within the C-terminal or N-terminal half of gC-1 or gC-2. All MAbs were able to bind to only one or the other of the two hybrid proteins, demonstrating that gC-2, like gC-1, contains at least two antigenic sites located in the two halves of the molecule and that the structures of the antigenic sites in both molecules are independent and rely on limited type-specific regions of the molecule to maintain epitope structure. To fine map amino acid residues which are recognized by site I type-specific MAbs, point mutations were introduced into site I of the gC-1 or gC-2 gene, which resulted in recombinant mutant glycoproteins containing one or several residues from the heterotypic serotype in an otherwise homotypic site I background. The recognition patterns of the MAbs for these mutant molecules demonstrated that (i) single amino acids are responsible for the type-specific nature of individual epitopes and (ii) epitopes are localized to regions of the molecule which contain both shared and unshared amino acids. Taken together, the data described herein established the existence of at least two distinct and structurally independent antigenic sites in gC-1 and gC-2 and identified subtle amino acid sequence differences which contribute to type specificity in antigenic site I of gC.
Glycoprotein C (gC) is one of numerous glycoproteins found on the surface of herpes simplex virus (HSV)-infected cells and within the viral envelope. Although this glycoprotein is not essential for virus production in cell culture (36) , gC serves multiple accessory functions, including the ability to bind the C3b component of complement (8, 10, 31) and to function in virus attachment to cells upon infection via heparan sulfate moieties on the cell surface membrane (18, 28) . Glycoprotein C is also a major viral antigen which elicits a strong humoral and cellular immune response during infection and plays an important role in the induction of herpetic eye disease in animal models of herpesvirus keratitis (4, 17, 48) .
Although many antibodies against HSV antigens react with both serotypes (HSV-1 and HSV-2), antibodies to gC are predominantly serotype specific (1, 6, 26, 33, 34, 41) , although cross-reactive antibodies do exist, particularly in polyclonal antisera (8, 51) . Therefore, this antigen appears to play an important role in defining type specificity of the virus. The type-specific antibody response to gC correlates with the 69% amino acid homology between gC-1 and gC-2 (5, 45) , compared with the much greater homology (85%) found among other highly immunogenic HSV glycoproteins (2, 46, 47) . The ability of gC-1 and gC-2 to elicit type-specific antibody responses could be due to antibody recognition of (i) structurally distinct and noncolinear regions of the two molecules or (ii) regions that are similar and colinear but contain key amino acid differences which contribute to epitope structure and determine antibody specificity.
Our laboratory previously reported on mutations which alter the antigenic structure of gC-1, resulting in a loss of recognition by some antibodies but not others (20, 30, 50) . These mutations were uncovered by using a panel of monoclonal antibodies (MAbs) to select a series of neutralization escape variants referred to as MAb-resistant (mar) mutants (20) . DNA sequencing and protein analyses demonstrated that the majority of mutant proteins contained single amino acid substitutions (19, 24, 50) . Some mutants, however, lacked gC in the virus envelope as a result of the presence of chain-terminating mutations and were therefore designated gC-rather than mar mutants (19, 24) . Analysis of the recognition patterns of MAbs with the mar mutants in neutralization assays revealed nine unique reactivity patterns. These functionally defined epitopes could be segregated into two distinct antigenic sites, each composed of multiple overlapping epitopes. Antibody binding competition assays confirmed the existence of two physically separate antigenic regions of the molecule, designated antigenic sites I and 11 (19, 24, 30) . Immunoprecipitation studies using chain-terminating mutants that express truncated gC molecules of various lengths provided evidence that these sites represent the physical antigenic determinants of gC which directly interact with the specific MAbs. Site II maintained g1-i S- (50) .
its antigenic structure in the absence of the carboxy-terminal half of the molecule and therefore resides in the aminoterminal portion of gC-1. DNA sequencing of the mar mutant gC genes identified mutations in codons for amino acids between residues 307 and 373 for site I mutants and between 129 and 247 for site II mutants (50) . These results and the later finding that a mar mutation in site I resulted in epitope seroconversion (25) , that is, the gC-1 mar mutant had acquired the ability to react with a gC-2-specific MAb, suggested the possibility that both gC molecules contain two similar antigenic sites. Moreover, the sites might be localized to colinear regions of the two molecules wherein subtle amino acid sequence differences create unique but overlapping type-specific epitopes. This idea was supported by a previous example of a type-specific epitope in glycoprotein D containing a single type-specific amino acid reported by Rawls et al. (35) .
This report confirms that the two dominant antigenic regions of gC-1 are distinct and that gC-2 also contains two similar antigenic regions. A more extensive genetic analysis of site I has further demonstrated that type-specific antibodies recognize individual amino acids in an environment of extensive homology between the two serotypes. It is concluded that at least for site I, amino acid sequence rather than conformational differences account for the unique and distinct antigenic character of gC-1 and gC-2.
MATERIALS AND METHODS
Plasmids. Plasmids were propagated in the DH5at strain of Escherichia coli and were isolated by lysis with sodium dodecyl sulfate (14) . Bacteria were transformed by standard methods (3). Transformants were analyzed by restriction enzyme digestions of DNA from quick plasmid preparations (minipreps) adapted from the boiling method (22) . The gC-1 gene was subcloned as a 3.4-kb PstI-HindIII fragment from pGC (23) . The gC-2 gene was subcloned as a 4.8-kb AatII fragment from pTYL302 (which contains the BamHI A fragment from strain 333 of HSV-2) (52). Each of these fragments was subcloned into pBS+ (Stratagene) to create pgClPH and pgC2Aat, respectively.
Site-directed mutagenesis was performed by the method of Kunkel et al. (27) . Mutant plasmids were detected by restriction enzyme digestion of miniprep DNA (22) followed by electrophoresis on 1 to 2% agarose gels. Some mutations caused changes in the sizes of small restriction fragments which were readily detectable on 5% polyacrylamide gels. When mutants were present at low frequencies, they were screened by colony hybridization (16) with the appropriate mutant oligonucleotide probe labeled with 32p, using T4 polynucleotide kinase (29) . Tetramethylammonium chloride was used for the filter washes to eliminate the effects of GC content on hybridization (49) . The point mutations were confirmed by dideoxy DNA sequencing (38) of the mutant plasmids. Schematic diagrams of the proteins encoded by the mutant genes are shown in Fig. 1 Fig. 1 .
MAbs. MAbs used were described previously (25, 30) . III188-4 was kindly provided by P. Spear (33) , and MP1, MP2, and MP5 were the generous gifts of G. Cohen (40) .
Cells and viruses. Vero and HEL cells, HSV-1 (strain KOS), and HSV-2 (strain 333) were propagated as described previously (20) . Viral DNA was isolated from lysates of infected cells or virions (37) . Construction (30) . One goal of these studies was to determine whether site I would also remain antigenically active when separated from site II of gC-1, which would demonstrate that both sites are structurally independent. If the sites are indeed independent, then the epitope structure of site I would not depend on the presence of the N-terminal portion of the molecule and vice versa. The experimental approach was to produce and study two chimeric gC gene products in which the N-terminal half of gC-1 was joined in frame to the C-terminal half of gC-2 (gCl-gC2) and the N-terminal half of gC-2 was joined in frame to the C-terminal half of gC-1 (gC2-gCl). Besides Fig. 2 . Because gC-1 is larger than gC-2 at the N terminus (511 amino acids versus 480 amino acids), the gC1-gC2 hybrid protein was expected to have an apparent molecular mass the same as that of gC-1 (130 kDa). For the same reason, the gC2-gCl hybrid protein was expected to have an electrophoretic mobility comparable to that of gC-2 (85 kDa). However, it was observed that the gC1-gC2 product migrated slightly faster than gC-1 and gC2-gCl migrated slightly slower than gC-2 ( Fig. 2) . Since the C-terminal portions of gC-1 and gC-2 contain the same number of amino acids, it could be surmised that differences in 0-linked glycosylation between the two molecules are most likely responsible for the apparent size differences.
Initial experiments sought to evaluate the reactivity patterns of the gC-specific MAbs with the hybrid proteins. If either antigenic site is dependent on the other to maintain epitope integrity, then some antibodies might not be expected to bind to the hybrid protein as a result of disruption of the site by the presence of heterotypic residues. The results show, however, that each MAb was able to bind to one of the two hybrid proteins (Fig. 2) . All 20 of the gC-1-reactive MAbs bound to the hybrid containing the appropriate antigenic site of gC-1. C13, a gC-1-specific MAb which binds to antigenic site II (the N-terminal site), immunoprecipitated gC from cells infected with KOS or gC1-gC2, the recombinant containing gC-1 sequence at the N-terminal site. Cll is a gC-1-specific MAb which binds to antigenic site I (the C-terminal site). This MAb bound to gC produced by cells infected with KOS or gC2-gCl, the recombinant containing gC-1 sequence at the C-terminal site.
The results with the gC-2-specific MAbs are consistent with the concept of two independent antigenic sites and showed that binding of the gC-2-specific MAbs could be mapped to one or the other of the two sites. The gC-2-specific MAb C2-3 bound gC from HSV-2 strain 333 and from gC2-gCl, the recombinant containing type 2 sequence at the N-terminal site (Fig. 2) , indicating that C2-3 binds to antigenic site II. C2-5, a gC-2-specific MAb, bound gC from cells infected with 333 and gC1-gC2, the recombinant containing type 2 sequence at the C-terminal site (Fig. 2) . This result is consistent with our previous finding that C2-5 binds to the C-terminal portion of gC-2 (25 (Fig. 3) . As expected, gC-1-specific MAbs bound to KOS-infected cells, whereas gC-2-specific MAbs did not; gC-2-specific MAbs bound 333-infected cells, and gC-1-specific MAbs did not. C13, a gC-1-reactive MAb which binds site II, and C2-5, a gC-2-reactive MAb which binds site I, both bound to cells infected with the gC1-gC2 virus, whereas MAbs Cll and C2-3 did not. Cll, a gC-1-specific MAb which binds site I, and C2-3, a gC-2-specific MAb which binds site II, both bound cells infected with the gC2-gCl virus, whereas MAbs C13 and C2-5 did not. These results are consistent with those of radioimmunoprecipitation using infected cell extracts and demonstrate that the antigenic structure of gC on the surface of infected cells correlates with the structure of gC extracted from infected cells.
Neutralization assays were carried out with four representative MAbs to evaluate the ability of the antibodies to bind the hybrid proteins present in virion envelopes (data not shown). In each case, the neutralization patterns for individual MAbs were consistent with the immunoprecipitation and flow cytometry data. This result confirmed that the antigenic sites of gC-1 and gC-2 are independent from one another when present in hybrid molecules in both virion and cellular membranes.
The results of these studies with chimeric gC molecules (summarized in Table 1 ) provide information on the overall antigenic structure of gC-1 and gC-2. First, the data confirm that antigenic sites I and II of gC-1 are independent of one another; that is, distal type-specific residues are not essential for maintenance of each antigenic site. For ously mapped mar mutations lie. It should be possible, therefore, to use a genetic approach to further characterize antigenic areas of the molecules and identify residues which play a crucial role in the formation of type-specific epitopes. Figure 4 shows the amino acid sequence of antigenic site I of gC-1 and gC-2 and the locations of mar mutations affecting the binding of gC-1-specific MAbs. The substitution of amino acids at the locations of mar mutations in gC-1 is expected to eliminate binding of the respective gC-1-reactive MAbs. By exchanging these amino acids for those found in gC-2 at these positions, it might be possible to introduce gC-2 epitopes into the gC-1 molecule. Likewise, the reciprocal changes in gC-2 might introduce the appropriate gC-1 epitopes that were mapped to this site. To test these predictions, site-directed mutagenesis was used to introduce one or four codon changes into antigenic site I of gC-1 and gC-2 (solid rectangles in Fig. 4) . The mutations were introduced at codons for amino acids which differ between the serotypes and were selected because they either represented mar mutations or were near these mutations.
Previous results showed that the gC-2-reactive MAb C2-5 was able to recognize and bind to the marC 11.1 and marC 14.1 mutant proteins (25) . This mutation resulted in the substitution of an arginine for a glutamine residue at position 307. Since arginine is present in gC-2 at the corresponding position 276 whereas the remainder of the marC 11.1/14.1 gC molecule contains the unchanged gC-1 sequence, it became clear that arginine was the critical gC-2 residue recognized by MAb C2-5. This finding indicated that substitution of the arginine residue with glutamine would render a gC-2 mutant resistant to neutralization by C2-5. It was predicted, therefore, that this substitution in the gC-2 background might also result in seroconversion allowing for recognition of gC-2 by C1l, a gC-1-reactive antibody. This mutation was engineered into the gC-2 coding sequence at codon 276 by site-directed mutagenesis and then introduced by marker transfer into the HSV-1 recombinant virus carrying the gC1-gC2 chimeric gene. The resultant cotransfection progeny were then neutralized with MAb C2-5, which enriched for recombinant progeny carrying the mutant gene with a single point mutation in site I of gC-2. Presence of the point mutation was verified by Southern blotting. Immunoreactive black plaque assays on neutralization escape progeny revealed that C2-5 failed to bind to developing plaques, whereas MAb Cll produced black plaques (data not shown).
This finding demonstrated that like the arginine-for-glutamine substitution in gC-1, the substitution of glutamine for arginine in gC-2 resulted in seroconversion of this epitope. It is concluded from these data that the type-specific epitopes recognized by MAbs Cll and C2-5 rely on this critical residue at positions 276 (gC-2) and 307 (gC-1). Despite the fact that these residues are at different amino acid positions in the molecules, they are at the same position when the two molecules are aligned for best-fit homology.
The hybrid gC1-gC2 protein with an arginine-to-glutamine substitution at the gC-2 amino acid position 276 was referred to as 276.2. 276.2[gC1-gC2] was tested for its ability to react with 26 MAbs to gC in radioimmunoprecipitation assays (examples are shown in Fig. 5 ). The patterns of binding of site II antibodies were the same as for wild-type gC-1 (and 11: 15. (Fig. 4) (Fig. 4) . This single amino acid may be sufficient for type specificity of the C15 epitope. However, the importance of the other three amino acids cannot be ruled out. These immunoprecipitation results were confirmed by neutraliza-VOL. 66, 1992 on August 14, 2017 by guest http://jvi.asm.org/ Downloaded from tion assay and flow cytometry using four site I antibodies (data not shown).
In total, these data indicate that first, an important component of site I of gC-1 lies within a cluster of only eight residues, four of which are unshared with type 2 (Fig. 4) . These eight residues, amino acids 305 through 312, include the locations of two mar mutations as well as the four amino acids which were changed in I.2[gC-1]. However, a role for other shared or unshared amino acids in the formation of these site I epitopes is likely, as demonstrated by marC 2.1 (Fig. 4) , which contains an amino acid change at position 373 that affects antigenic structure, and more dramatically by gC-44, described below. Second, it appears likely that although at least one gC-2 epitope is colinear with the type 1 epitope cluster, there may be other noncolinear type 2 epitopes in this region. In general, however, type specificity appears to rely on subtle differences in sequence between gC-1 and gC-2 localized to similar molecular regions.
Characterization of the gC-44 virus. The gC-44 mar mutant of strain KOS was reported earlier to lack an expressed form of gC, as judged from its resistance to neutralization by a pool of MAbs specific for site I (19) . Closer examination revealed that this mutant did in fact express a gC polypeptide, and DNA sequencing of the mutant gene identified a single nucleotide change resulting in replacement of the serine residue at position 329 in site I with phenylalanine (24) (Fig. 4) .
This mutant proved to be useful in the further analysis of site I. As with the other mutants, gC-44 was first studied by radioimmunoprecipitation using our panel of type-specific MAbs. Immunoprecipitation by gC-1 site II-reactive MAbs was normal, whereas antibodies specific for site I precipitated a small amount of protein (Fig. 6) . The reduced level of immunoprecipitation was most apparent with the mature form of the protein; the precursor form displayed levels comparable to those of the wild type. This finding suggested that complete glycosylation is important for maintaining the antigenic structure, either because of the effect of glycosylation on conformation or because of direct involvement of carbohydrate moieties in antibody binding.
As shown in Fig. 6 , the site II-specific antibody C13 immunoprecipitated the gC-44 protein as efficiently as did the wild-type protein. In contrast, Cl, Cll, C14, and C15, all site I-reactive antibodies, immunoprecipitated the gC-44 protein poorly compared with wild-type gC-1. Immunoprecipitation of the gC-44 protein by Cl and C14 was especially inefficient and was detectable only after very long exposure of film to the gels. None of the gC-2-reactive MAbs bound this mutant protein, as expected since the mutated residue is conserved in the two serotypes and therefore is unlikely to contribute to type specificity. These results were confirmed by neutralization assay and flow cytometry using a site II-specific antibody control and the four site I-specific antibodies mentioned above (data not shown). Neutralization of gC-44 with site I-reactive MAbs was minimal, confirming our earlier results (19) MAbs in binding assays (13) . The fact that disruption of site I occurred without affecting site TI supports the inference that site II is independent of site I.
DISCUSSION
This study was undertaken to compare the antigenic components of glycoprotein C encoded by HSV-1 and HSV-2. The interest in these molecules stems from the fact that they play important roles in the immunobiology of infection and possess the interesting property of eliciting primarily type-specific responses during infection, in contrast to most other HSV glycoproteins (1, 6, 7, 12, 26, 33, 34, 39, 41) . Why the antigenic differences between gC-1 and gC-2 are distinct is unknown but may be due to certain functional characteristics of these molecules. The C3b binding and virus attachment properties differ for gC-1 and gC-2 (10, 28) , which may contribute to differences in their antigenic properties. There also appears to exist limited overlap between antigenic and structural features of gC which play a role in its binding activity for the C3b component of complement (11) and perhaps other features such as attachment to cell membranes during the early stages of infection. This limited overlap between antigenic domains and functional domains may allow further divergence in antigenic structure between the two molecules.
In this study, we attempted to use extensive information on the antigenic structure of gC-1 as a starting point to extend our epitope analyses to gC-2. In particular, a major emphasis was placed on determining whether similar molecular structures of both proteins contain dominant epitope clusters. If so, we wished to investigate whether the largely type-specific antibody response to these antigenic sites is determined by single amino acid differences in largely conserved domains or whether the antigenic sites in these regions are rather dissimilar and unrelated. The study was also prompted by our earlier finding that a single mutation in a type 1-specific epitope converted it to one recognized by a type 2-specific antibody (25) , raising the possibility that the antigenic sites in these molecules are colinear and probably similar.
Two types of intertypic recombinant gC genes were con- Studies of hybrid proteins revealed that antigenic sites I and II of both gC-1 and gC-2 are structurally independent of one another in that they retain their site-specific antigenicity when physically joined to part of the heterotypic molecule. The gC1-gC2 protein was bound by anti-HSV-1 MAbs to site II (N-terminal) and anti-HSV-2 MAbs to the C-terminal half of gC-2, while the gC2-gC1 protein was bound by HSV-2-specific antibodies to the N-terminal half of gC-2 and HSV-1-specific antibodies to site I ( Table 1) . The results also demonstrated the existence of at least one antigenic site in each of the two halves of gC-2, as previously shown for gC-1.
Results with point mutants confirmed the independence of the antigenic sites and provided a more detailed understanding of the structure of site I. By introducing specific point mutations in site I, it was possible to eliminate binding of some site I-reactive MAbs and to acquire binding of other site I-reactive MAbs without affecting the binding of site II-reactive MAbs. Analysis of mutant gC-1 molecules containing gC-2 amino acids and mutant gC-2 molecules containing the respective gC-1 amino acids yielded reciprocal results; that is, gC-2-specific antibodies recognized the substituted gC-2 residues in the otherwise gC (Table 1) . These results provide an example of sequence arrangements which are responsible for the serotype specificity of gC. The MAbs bound to areas of the molecule which are highly homologous between the two serotypes, meaning that type specificity in this case is not due to antibody recognition of divergent areas of the molecules. This finding rules out an early hypothesis to explain type specificity (5) based on recognition of nonhomologous areas of the molecules and suggests that the secondary structure of gC-1 and gC-2 may be similar because it was possible to effect serotype conversion of individual epitopes by introducing point mutations. If the MAbs were binding to areas of the molecules with limited homology and different secondary structure, single point mutations would not be expected to introduce epitopes specific to the heterotypic serotype. Overall, the results demonstrate that type specificity is due to the presence of different individual amino acids in a common structural framework, consistent with the hypothesis that antibodies to gC recognize areas possessing substantial homology between the molecules. These individual amino acids could be directly involved in binding as a result of their hydrophilic nature and accessibility on the antigen surface or, alternatively could be responsible for limited conformational differences which affect the spatial configuration of residues shared by the two molecules, thereby creating unique epitopes.
Results with type 2-specific antibodies suggest that site I of gC-2 may be composed of two or more subsites. gC-2 site I encoded by the 276.2[gC1-gC2] and I.1[gC-2] viruses lost the ability to bind MAb C2-5, while gC-1 from marC 11.1 and I.2[gC-11 gained the ability to be recognized by this MAb (Table 1) . However, binding of three other type 2-specific MAbs to site I was not altered by the residue substitutions. This finding indicates that the epitopes to which these three MAbs bind do not include the four amino acids which were changed in gC-2 or that these changes do not affect the conformation of the epitopes recognized by these MAbs. It is possible that the epitopes to which these three MAbs bind do indeed overlap the C2-5 epitope, but there is no evidence for this. Seidel-Dugan et al. (40) examined serotype 2-reactive MAbs and found that MP1 (group III) and III188-4 (group V), two of the site I antibodies, do not compete for binding, suggesting that site I of gC-2 consists of more than one antigenic site. Because of the high degree of homology between gC-1 and gC-2, gC-1 may also contain more than one antigenic site in the region identified as site I. Further site-specific mutations within site I could prove useful for delineating the specific residues involved in this other potential antigenic site.
Point mutations may result in structural changes without complete loss of antibody binding, as observed with the gC-44 mutant. This mutant contains a point mutation in site I which reduced the level of binding of all site I-specific antibodies without affecting binding of site II-specific antibodies ( Table 1 ). The reduction in binding was most significant for the mature, fully glycosylated form of the protein, suggesting that the mutation affects the ability of the protein containing complex-type oligosaccharides to fold into its wild-type conformation. Examples of HSV epitopes disrupted by altered glycosylation have been observed for glycoprotein D (43) . In this case, elimination of one site of N-linked glycosylation resulted in the loss of some but not all epitopes within an antigenic site, demonstrating that altered glycosylation can have a localized effect without affecting other parts of the molecule. Investigation into the glycosylation of gC has indicated that some epitopes are dependent, some are independent, and some are masked by oligosaccharides (32, 42) . Site II-reactive MAbs bound to the gC-44 mutant glycoprotein normally, which confirms the independence of site II from site I. The observation that site I-specific MAbs bound poorly, if at all, to gC from gC- 44 showed that a single point mutation disrupted several epitopes and possibly the entire antigenic site (site I). This disruption of structure suggests that the site I epitopes are conformationally dependent and may consist of individual amino acids displayed on the surface of the structural framework. In addition, the possibility that a single mutation may disrupt an entire antigenic site suggests a mechanism for antigenic shift in which a strain of virus suddenly VOL. 66, 1992 on August 14, 2017 by guest http://jvi.asm.org/ Downloaded from shows a drastic change in its immunological profile. The findings in this report showed that the gC-44 virus, which was previously believed to be deficient in gC, does in fact express and retain a gC molecule in its envelope. On the basis of these results, we propose that this mutant virus be renamed gC44 to reflect the presence of gC. The significant homology between gC-1 and gC-2 and the fact that the amino acid at the position of the gC44 mutation is shared between the two molecules suggest that this residue is also important to the antigenic structure of site I in gC-2. This possibility could be investigated by testing a gC-2 molecule containing the same substitution found in gC44 with site I-specific MAbs in order to further examine the importance of this residue.
Comparison of the gC-1 and gC-2 sequences in the vicinity of the mar mutations (see Fig. 4 for site I sequences) illustrates that the epitopes contain some critical amino acids which are different in the two serotypes and are therefore good candidates for determinants of type specificity. On the other hand, some mar mutations are found at residues which are identical in the two molecules, demonstrating that shared amino acids are also antigenic or contribute to the overall structure of the epitope. One of three mar mutations in site I and six of seven mar mutations in site II (50) are found at residues which are identical in gC-1 and gC-2, indicating that type-common residues are important to antigenic structure. Because they are interspersed with type-specific amino acids, shared amino acids can apparently contribute to epitopes which are serotype specific. Site I of gC-1 is currently defined as spanning amino acids 307 through 373 (50) . The primary amino acid sequence within this region is 79% homologous with the gC-2 sequence. The 6 amino acids from the marC 11.1 mutation to the marC 15.1 mutation are 50% homologous, while 11 amino acids surrounding the marC 2.1 mutation are identical to the respective gC-2 residues, showing that there is no correlation between nonhomology and importance to antigenic structure. In the case of marC 2.1, an effect on antigenic structure of the mutation is not surprising since the altered residue is proline, an amino acid important to the secondary structure of proteins.
T-cell responses to gC, like humoral responses, tend to be type specific (7, 12, 39) . The gC variants created in this study may therefore be useful for examination of T-cell determinants. The utility of the point mutants would depend on the overlap of antibody epitopes and T-cell determinants, however.
The studies described here show that (i) gC-2 contains at least two antigenic sites in locations similar to those found in gC-1, (ii) antigenic sites I and II of gC-1 and gC-2 are independent of one another, (iii) some epitopes of site I in gC-1 and gC-2 are colinear, (iv) the type specificity of antigenic site I is due to subtle amino acid differences between the two serotypes, and (v) epitopes of site I in gC-1 are conformationally dependent. In addition, the results imply that alteration of a few critical amino acids should allow the virus to evade the immune system of the host.
